Precigen (PGEN) Aktie Kurs

Precigen Inc is primarily active in the biotechnology industry. As a leading biotech company, Precigen focuses on developing advanced gene and cell therapies, genetic medicines, and agricultural biotechnology solutions. The company harnesses the power of innovative gene editing platforms to address significant unmet needs in healthcare and food production sectors. Precigen Inc leverages its cutting-edge technologies and extensive expertise to create transformative solutions for various genetic disorders, chronic diseases, and sustainable agriculture practices. With its commitment to innovation and scientific progress, Precigen Inc continues to play a vital role in shaping the biotechnology landscape.

The main competitors of Precigen Inc in the market include companies like Intrexon Corporation, Editas Medicine, CRISPR Therapeutics, and Sangamo Therapeutics.

Precigen Inc, formerly known as Intrexon Corporation, is a biotechnology company based in Germantown, Maryland. Established in 1998, Precigen focuses on applying synthetic biology to solve complex problems across various industries. The company is driven by a mission to create biologically-based solutions to improve the quality of life and promote sustainability. Precigen has expertise in the development and commercialization of advanced gene and cellular therapies, as well as agricultural biotech solutions. With its innovative approach and cutting-edge technologies, Precigen has established itself as a leader in the field of synthetic biology, continuously striving to push boundaries and make a positive impact on the world.

Precigen Inc, formerly known as Intrexon Corporation, has achieved several noteworthy milestones throughout its history. The company, a leader in synthetic biology, has successfully developed and commercialized various advanced technologies and solutions. Precigen Inc has made significant breakthroughs in the areas of gene and cell therapy, as well as synthetic gene technologies. These accomplishments include the successful clinical trials of their CAR-T therapy candidates, the development of their UltraVector® platform, and the creation of novel genetically modified organisms. Precigen Inc's continuous dedication to innovation and cutting-edge science has positioned them as one of the prominent players in the field.

Precigen Inc is primarily present in the United States and has its headquarters in Germantown, Maryland.

Precigen Inc represents a strong commitment to innovation, integrity, and social responsibility. As a leading biotechnology company, Precigen pioneers advancements in the field of genetic research. With a dedicated focus on developing therapies and solutions for human health, they prioritize scientific excellence and cutting-edge technology. Led by a team of experts, Precigen emphasizes collaboration and strategic partnerships to achieve their mission of transforming lives through innovative healthcare solutions. Through their dedication to improving global health outcomes and their unwavering dedication to their core values, Precigen Inc stands as a trusted name in the biotech industry.

Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 18,00 USD for Precigen-aktien (median: 18,00 USD), svarende til +250,2 % i forhold til seneste kurs. Konsensus bygger på 10 analytikervurderinger.

Precigen Analytikerens Kursmål 2026

10 analytikere vurderer i øjeblikket Precigen-aktien: 8 anbefaler køb, 2 hold og 0 salg. For 2026 forventer analytikere, at Precigen genererer omsætning på 238,71 Mio. USD og indtjening pr. aktie på 0,19 USD.

Precigen Analytikerens Kursmål 2026

Omregnet til den aktuelle valutakurs handles Precigen-aktien til 4,59 EUR (5,14 USD).

Precigen-aktien (PGEN) er noteret på 5 børser, herunder: NASDAQ (PGEN), SIX (Zürich) (I5X.SW), Frankfurt (I5X), München (I5X.MU), Düsseldorf (I5X.DU).

Precigen Inc, founded in 2000, is a biotechnology company headquartered in Germantown, Maryland. The company specializes in the development and application of gene editing technologies used in the therapy of severe diseases and genetic disorders. Precigen's business model is based on four main areas: therapeutic product development, agricultural biotechnology, industrial biotechnology, and research and development of genomic technology. Precigen develops therapeutics aimed at curing or alleviating serious diseases such as cancer and genetic disorders using its proprietary gene editing technology platforms like UltraPrecise, ActoBiotics, and X-Press. The company also works in agricultural biotechnology to develop innovative solutions for improving agricultural yields and promoting sustainable farming. In industrial biotechnology, Precigen leverages its expertise to contribute to the development of renewable energy and biofuels. The company explores and develops new technologies in genomics for diagnostic, therapeutic, and disease prevention purposes. Precigen emphasizes the ethical and social aspects of genetic research. Additionally, the company offers products and services based on its technology platforms, such as UltraVector, a proprietary vector design tool that supports DNA construction and gene editing processes. Precigen also holds a license for obtaining plasmid DNA, which helps reduce costs in the production of therapeutics or biotherapeutics. Overall, Precigen has developed a wide range of technologies and applications to assist customers in overcoming complex challenges in various fields, with a focus on gene editing technology and its applications in therapy, agriculture, industrial biotechnology, and genomic research.

forventet-omsætningen for Precigen er 238,71 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Precigen er 60,63 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Precigen er i øjeblikket 26,53. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Precigen-aktien.

Pris-til-salgs-forholdet (P/S) for Precigen er i øjeblikket 6,74. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Precigen-aktien.

AlleAktien-kvalitetsscore for Precigen er 4/10.

ISIN for Precigen er US74017N1054. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Precigen er A2PZG1. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Precigen er PGEN. Tickersymbolet bruges til at handle Precigen-aktier på børsen.